Korro Bio Q3 net loss narrows to $17.55 million
KRRO•Korro Bio’s third-quarter 2026 net loss narrowed year over year to $17.55 million, with no collaboration revenue recorded. It reported $124.8 million in cash, cash equivalents and marketable securities, supporting a runway into the second half of 2028.
1. Quarterly results and pipeline
Korro Bio reported a third-quarter 2026 net loss of $17.55 million, narrowed year over year, and no collaboration revenue during the agreed 12-month pause in its Novo Nordisk collaboration. The company said its $124.8 million in cash, cash equivalents and marketable securities at September 30 supports a runway into the second half of 2028; dosing has begun in healthy volunteers in the KRRO-121 Phase 1/2 ANCHOR trial, with interim data expected in the second half of 2027.
